Pharming Group (NASDAQ:PHAR) Shares Up 8.6% – Time to Buy?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR)’s stock price shot up 8.6% during trading on Wednesday . The company traded as high as $17.09 and last traded at $17.15. 6,783 shares were traded during trading, a decline of 19% from the average session volume of 8,357 shares. The stock had previously closed at $15.79.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on PHAR shares. Zacks Research raised shares of Pharming Group from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 6th. Weiss Ratings downgraded Pharming Group from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $30.00.

Pharming Group Trading Up 8.6%

The company’s fifty day moving average is $14.39 and its 200-day moving average is $12.17. The company has a debt-to-equity ratio of 0.35, a current ratio of 3.16 and a quick ratio of 2.39. The company has a market capitalization of $1.17 billion, a PE ratio of -1,713.29 and a beta of 0.03.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, November 6th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.05. The business had revenue of $97.30 million for the quarter, compared to analysts’ expectations of $98.22 million. Pharming Group had a return on equity of 0.46% and a net margin of 0.30%. Pharming Group has set its FY 2025 guidance at EPS. On average, analysts anticipate that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current fiscal year.

Institutional Trading of Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC acquired a new position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,979 shares of the company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.